Literature DB >> 24072520

Equipoise abandoned? Randomization and clinical trials.

R Kurzrock1, D J Stewart2.   

Abstract

Mesh：

Year:  2013        PMID： 24072520     DOI： 10.1093/annonc/mdt358

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  11 in total

1.  Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US Food and Drug Administration trial-level and patient-level analyses.

Authors:  Gideon M Blumenthal; Stella W Karuri; Hui Zhang; Lijun Zhang; Sean Khozin; Dickran Kazandjian; Shenghui Tang; Rajeshwari Sridhara; Patricia Keegan; Richard Pazdur
Journal:  J Clin Oncol       Date:  2015-02-09       Impact factor: 44.544

Review 2.  Precision medicine needs randomized clinical trials.

Authors:  Everardo D Saad; Xavier Paoletti; Tomasz Burzykowski; Marc Buyse
Journal:  Nat Rev Clin Oncol       Date:  2017-02-07       Impact factor: 66.675

3.  Health policy: The right to try is embodied in the right to die.

Authors:  Benjamin A Cohen-Kurzrock; Philip R Cohen; Razelle Kurzrock
Journal:  Nat Rev Clin Oncol       Date:  2016-05-24       Impact factor: 66.675

Review 4.  Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval.

Authors:  Bishal Gyawali; Spencer Phillips Hey; Aaron S Kesselheim
Journal:  JAMA Intern Med       Date:  2019-07-01       Impact factor: 21.873

Review 5.  Phase I trials as valid therapeutic options for patients with cancer.

Authors:  Jacob J Adashek; Patricia M LoRusso; David S Hong; Razelle Kurzrock
Journal:  Nat Rev Clin Oncol       Date:  2019-09-02       Impact factor: 66.675

6.  N of 1 case reports of exceptional responders accrued from pancreatic cancer patients enrolled in first-in-man studies from 2002 through 2012.

Authors:  Ignacio Garrido-Laguna; Danielle Tometich; Nan Hu; Jian Ying; Katherine Geiersbach; Jonathan Whisenant; Kai Wang; Jeffrey S Ross; Sunil Sharma
Journal:  Oncoscience       Date:  2015-03-14

7.  Very large treatment effects in randomised trials as an empirical marker to indicate whether subsequent trials are necessary: meta-epidemiological assessment.

Authors:  Myura Nagendran; Tiago V Pereira; Grace Kiew; Douglas G Altman; Mahiben Maruthappu; John P A Ioannidis; Peter McCulloch
Journal:  BMJ       Date:  2016-10-27

8.  Oncology Drug Approvals: Evaluating Endpoints and Evidence in an Era of Breakthrough Therapies.

Authors:  Gideon M Blumenthal; Paul G Kluetz; Julie Schneider; Kirsten B Goldberg; Amy E McKee; Richard Pazdur
Journal:  Oncologist       Date:  2017-06-02

9.  Conveying Equipoise during Recruitment for Clinical Trials: Qualitative Synthesis of Clinicians' Practices across Six Randomised Controlled Trials.

Authors:  Leila Rooshenas; Daisy Elliott; Julia Wade; Marcus Jepson; Sangeetha Paramasivan; Sean Strong; Caroline Wilson; David Beard; Jane M Blazeby; Alison Birtle; Alison Halliday; Chris A Rogers; Rob Stein; Jenny L Donovan
Journal:  PLoS Med       Date:  2016-10-18       Impact factor: 11.069

10.  The importance of greater speed in drug development for advanced malignancies.

Authors:  David J Stewart; Andrew A Stewart; Paul Wheatley-Price; Gerald Batist; Hagop M Kantarjian; Joan Schiller; Mark Clemons; John-Peter Bradford; Laurel Gillespie; Razelle Kurzrock
Journal:  Cancer Med       Date:  2018-03-30       Impact factor: 4.452
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.